Abstract: The present invention is a physical pathogen reduction method and apparatus for controlling or eliminating transfusion-transmittable infections. This purely physical technique does not involve the use of heat, chemicals and/or irradiation, each of which has significant drawbacks in the pathogen reduction of human plasma. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the natural biological activity. integrity and potency of the treated plasma. The method uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma, using novel blood plasma bags. The apparatus is in the form of a bench-top or mobile transportable unit, which can be used in hospitals, blood banks, medical facilities and hot zones in developing countries for the clearance of viruses from human plasma.

Abstract: The present invention is for a continuous-flow pathogen reduction apparatus and method, based purely on pathogen inactivation physical principles, for controlling or eliminating trans fusion-transmittable infections from emerging pathogens, pandemic viruses, and bioterrorism threats. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in human plasma and biologies, while retaining the natural bioactivity, integrity and potency of the treated biologic. The method uses critic al, near-critical or supercritical fluids for viral and pathogen reduction of plasma and biologies. The apparatus is designed to rapidly process high volumes of plasma and biologies with high levels of pathogen reduction in a continuous flow fashion.

Abstract: A method and apparatus for reducing or inactivating pathogens in units of whole blood. A plurality of superparamagnetic nanoparticles (SPN) is coated with a mixture of chemiluminescence light-generating compounds and photodynamic broad-spectrum anti-viral compounds, and the mixture in introduced into a bag of whole blood. A rapidly-changing electromagnetic field is applied to the bag to cause uniform distribution of the nanoparticles within the whole blood throughout all regions of the blood bag, including the opaque interior of the bag. The blood is processed for a predetermined processing time period, during which the chemiluminescence light activates the broad-spectrum antiviral capacity of the photodynamic compounds to achieve reduction or inactivation of pathogens throughout the blood bag. After the processing time is elapsed, the nanoparticles are removed from the processed blood by a magnetic field.

Abstract: This invention is for improved extracting, separating, and manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for central nervous system (CNS) and peripheral nervous system (PNS) disorders such as pain, opioid use disorder, anxiety, epilepsy, nausea and vomiting, Multiple sclerosis and other indications by the National Institute of Health (NIH) and other researchers. This invention first established optimum conditions for the selective SuperFluids™ [supercritical fluids and near-critical fluids with or without polar co-solvents such as alcohols] fractionation of Cannabis sativa to isolate CBD, CBDA, ?9-THC, ?9-THCA and other cannabinoids ?9-THC; then defined SuperFluids™ chromatographic purification conditions for the further purification of CBD, CBDA, ?9-THC, ?9-THCA with absolute purities >98.5%. This invention is for methods and apparatus to manufacture pharmaceutical-grade CBD and CBDA (98.

Abstract: A method is disclosed for producing targeted nanoencapsulated therapeutics in a microgravity environment using supercritical, critical and near-critical fluids with and without polar cosolvents. Using the disclosed technology, nanosomes for delivering Bryostatin-1 and other Bryoids are produced in microgravity. The resulting nanosomes are smaller, more uniform, with a higher surface area to volume than those produced in gravity-based environments and have an average diameter between 0.001 to 20.000 nanometer. The resultant therapeutics may be used for treating chronic diseases such as cancer, HIV, and Alzheimer's disease.

Abstract: The present invention is directed to methods and apparatus for creating a sustained release pathogen vaccine for COVID-19, influenza, HIV and other infectious human and animal viruses and pathogens using supercritical, critical, or near-critical fluids with or without polar cosolvents for simultaneously inactivating virions and pathogens, and encapsulating the inactivated virions and pathogens in biodegradable polymer nanospheres for administration to a patient. The present invention continuously inactivates SARS-CoV-2, influenza, HIV and other infectious human and animal viruses and pathogens, and nanoencapsulates the inactivated virions and pathogens in biodegradable polymer nanospheres to provide a safe and effective sustained-release vaccine, especially for the frail and elderly.

Abstract: This invention is for methods to quantify the inhibition of 5-HT induced contraction of human intestinal smooth muscle and an assay to measure the effects of compounds on nausea, irritable bowel syndrome and irritable bowel disease. This invention can be used to measure the incidence and severity of nausea, and can be used as quality control assay for developing and releasing medications for controlling nausea and emesis.

Abstract: This invention relates to a composition of matter using enhanced gingerols for treating nausea and emesis associated with cancer chemotherapy, pregnancy, elective surgery, radiation therapy, motion sickness, and drug medications, use and schedule of use as well as methods of making. A method of making the enhanced gingerols features supercritical, critical and near-critical fluids with and without polar cosolvents. The capsules include an enhanced extract of ginger rhizome wherein said ginger rhizome has a starting mass and said extract has a 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass and said ratio of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass to starting mass is 90-100%.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to dosage forms for treating inflammation and rejection in transplantation injuries, graft versus host disease and stem cell transplants with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Abstract: Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease.

Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids, naltrexone and a combination of cannabinoids and naltrexone as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized sphere having a diameter of about 100 to 500 nanometers having a shell comprising a biodegradable polymer containing a cannabinoid, naltrexone and a combination of a cannabinoid and naltrexone in a deareated buffer. A featured cannabinoid is cannabidiol (CBD).

Abstract: Embodiments of the present invention are directed to the administration of co-encapsulated bryostatins and retinoids for the treatment of disease, wherein the co-encapsulated bryostatins and retinoids synergistically increase expression of alpha secretase activity in patients. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and ophthalmic diseases such as glaucoma.

Abstract: Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.

Abstract: This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone.

Abstract: Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.